In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spine Arthroplasty's Next Generation

Executive Summary

Spine arthroplasty--replacing either the entire disc or simply the nucleus--is one of the most promising new therapies to treat patients with herniated discs and degenerative disc disease. But the technology has had a rocky history: rushed into patients too soon, without proper clinical trials, say critics, disc replacement languished in Europe and took a long time to attract interest in the US. Moreover, first generation arthroplasty products, most notably discs, had several drawbacks that limited adoption--some were very hard to implant, for example, while others were too stiff and tended to extrude. Companies like Disc Dynamics hope to ride the wave of interest in disc and nucleus replacement as it develops new technology that is both superior to first generation products and backed by the proper kinds of clinical studies.
Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002113

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel